Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702616 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
The approved single-agent doses of mitoxantrone and cabazitaxel were safely combined. The combination led to durable tumor responses in most patients. Further study of the combination is warranted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Rahul M.D., Alan M.D., Charles J. M.D., Andrea M.D., Christina M.D., Won M.D., Terence M.D., Amy M. M.D., Tammy N.P., Mallika M.D., Li Ph.D., Mina B.S., Eric B.S., Jeffrey B.S., Eric J. M.D.,